952 related articles for article (PubMed ID: 28968684)
1. Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.
McCoy SS; Reed TJ; Berthier CC; Tsou PS; Liu J; Gudjonsson JE; Khanna D; Kahlenberg JM
Rheumatology (Oxford); 2017 Nov; 56(11):1970-1981. PubMed ID: 28968684
[TBL] [Abstract][Full Text] [Related]
2. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.
Ghosh AK; Bhattacharyya S; Lakos G; Chen SJ; Mori Y; Varga J
Arthritis Rheum; 2004 Apr; 50(4):1305-18. PubMed ID: 15077315
[TBL] [Abstract][Full Text] [Related]
3. From microvasculature to fibroblasts: Contribution of anti-endothelial cell antibodies in systemic sclerosis.
Corallo C; Franci B; Lucani B; Montella A; Chirico C; Gonnelli S; Nuti R; Giordano N
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):93-103. PubMed ID: 25816411
[TBL] [Abstract][Full Text] [Related]
4. PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis.
Wei J; Ghosh AK; Sargent JL; Komura K; Wu M; Huang QQ; Jain M; Whitfield ML; Feghali-Bostwick C; Varga J
PLoS One; 2010 Nov; 5(11):e13778. PubMed ID: 21072170
[TBL] [Abstract][Full Text] [Related]
5. IL-22 capacitates dermal fibroblast responses to TNF in scleroderma.
Brembilla NC; Dufour AM; Alvarez M; Hugues S; Montanari E; Truchetet ME; Lonati P; Fontao L; Gabrielli A; Vettori S; Valentini G; Boehncke WH; Meroni P; Chizzolini C
Ann Rheum Dis; 2016 Sep; 75(9):1697-705. PubMed ID: 26452537
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target.
Piera-Velazquez S; Fertala J; Huaman-Vargas G; Louneva N; Jiménez SA
Rheumatology (Oxford); 2020 Oct; 59(10):3092-3098. PubMed ID: 32442272
[TBL] [Abstract][Full Text] [Related]
7. The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy.
Fang F; Liu L; Yang Y; Tamaki Z; Wei J; Marangoni RG; Bhattacharyya S; Summer RS; Ye B; Varga J
Arthritis Res Ther; 2012 Oct; 14(5):R229. PubMed ID: 23092446
[TBL] [Abstract][Full Text] [Related]
8. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
[TBL] [Abstract][Full Text] [Related]
9. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses.
Wei J; Zhu H; Komura K; Lord G; Tomcik M; Wang W; Doniparthi S; Tamaki Z; Hinchcliff M; Distler JH; Varga J
Ann Rheum Dis; 2014 Feb; 73(2):446-54. PubMed ID: 23515440
[TBL] [Abstract][Full Text] [Related]
10. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts.
Brembilla NC; Montanari E; Truchetet ME; Raschi E; Meroni P; Chizzolini C
Arthritis Res Ther; 2013 Oct; 15(5):R151. PubMed ID: 24289089
[TBL] [Abstract][Full Text] [Related]
11. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R
Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-130b regulates scleroderma fibrosis by targeting peroxisome proliferator-activated receptor γ.
Luo H; Zhu H; Zhou B; Xiao X; Zuo X
Mod Rheumatol; 2015 Jul; 25(4):595-602. PubMed ID: 25547017
[TBL] [Abstract][Full Text] [Related]
13. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.
Farina G; Lemaire R; Pancari P; Bayle J; Widom RL; Lafyatis R
Ann Rheum Dis; 2009 Mar; 68(3):435-41. PubMed ID: 18408251
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.
Carulli MT; Ong VH; Ponticos M; Shiwen X; Abraham DJ; Black CM; Denton CP
Arthritis Rheum; 2005 Dec; 52(12):3772-82. PubMed ID: 16320328
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
[TBL] [Abstract][Full Text] [Related]
16. IL-17A Dissociates Inflammation from Fibrogenesis in Systemic Sclerosis.
Dufour AM; Borowczyk-Michalowska J; Alvarez M; Truchetet ME; Modarressi A; Brembilla NC; Chizzolini C
J Invest Dermatol; 2020 Jan; 140(1):103-112.e8. PubMed ID: 31276679
[TBL] [Abstract][Full Text] [Related]
17. Dysfunctional Keratinocytes Increase Dermal Inflammation in Systemic Sclerosis: Results From Studies Using Tissue-Engineered Scleroderma Epidermis.
Russo B; Borowczyk J; Boehncke WH; Truchetet ME; Modarressi A; Brembilla NC; Chizzolini C
Arthritis Rheumatol; 2021 Jul; 73(7):1311-1317. PubMed ID: 33497035
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?
Corallo C; Cheleschi S; Cutolo M; Soldano S; Fioravanti A; Volpi N; Franci D; Nuti R; Giordano N
Arthritis Res Ther; 2019 Jun; 21(1):152. PubMed ID: 31234888
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis.
Corallo C; Pinto AM; Renieri A; Cheleschi S; Fioravanti A; Cutolo M; Soldano S; Nuti R; Giordano N
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):69-75. PubMed ID: 31365333
[TBL] [Abstract][Full Text] [Related]
20. The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.
Liang R; Šumová B; Cordazzo C; Mallano T; Zhang Y; Wohlfahrt T; Dees C; Ramming A; Krasowska D; Michalska-Jakubus M; Distler O; Schett G; Šenolt L; Distler JH
Ann Rheum Dis; 2017 Apr; 76(4):756-764. PubMed ID: 27793816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
